Purpose: Although MAGEC2 was first cloned from a human hepatocellular carcinoma (HCC) cDNA library by serum screening, the detailed attributes of MAGEC2 in HCC have rarely been elucidated. Patients and methods: In this study, The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were consulted to analyse the expression of MAGEC2 mRNA in liver cancer. Immunohistochemistry (IHC) analysis was performed to detect MAGEC2 expression in HCC, and the relationship between MAGEC2 expression and the clinicopathological characteristics of HCC patients was evaluated. Then, we employed the short hairpin (sh)RNAmediated knockdown of MAGEC2 in HCC cell lines to explore the function of MAGEC2 in HCC development. Finally, the expression of epithelial-mesenchymal transition (EMT) markers in HCC xenografts and clinical samples was investigated.
Introduction
Hepatocellular carcinoma (HCC) has become the most common leading cause of cancer-related mortality worldwide. 1 In China, the township of Qidong in Jiangsu
Province is one of the highest endemic areas for HCC deaths globally. 2 The tumourigenesis of HCC is complicated, and several factors contribute to HCC development, including hepatitis B or C virus infection, chronic alcohol consumption and nonalcoholic fatty liver disease. 3 Although the survival rates for HCC have improved because of the development of therapeutic strategies in recent years, the overall prognosis is still unsatisfactory. 4 It is highly critical to identify informative molecular biomarkers and to understand the mechanisms of hepatocarcinogenesis for HCC.
Melanoma-associated antigens (MAGEs) represent a special type of tumour antigen that is highly expressed in tumours but weakly expressed in normal tissues. 5 Because of their unique characteristics, MAGEs are recognized as ideal targets for cancer immunotherapy, and several MAGE-based immunotherapy strategies have been developed. 6 MAGEC2 (HCA587) was first cloned from a human HCC cDNA library by serum screening, and it is highly expressed in several types of tumours. 7 A high incidence of MAGEC2 expression has been reported in larynx squamous cell carcinoma and is remarkably correlated with an advanced clinical stage. 8 A recent pilot study also reported that MAGEC2 could be a potential biomarker for triple-negative breast cancer. 9 However, the detailed characteristics and mechanisms of MAGEC2 in HCC are inadequately understood.
In the present study, we first examined MAGEC2 expression in HCC tissues and evaluated its association with the clinicopathological attributes of HCC patients. Then, we constructed MAGEC2-knockdown (sh-MAGEC2) models in HCC cell lines to detect the characteristics of MAGEC2 in HCC development, both in vitro and in vivo. Finally, we explored the role of MAGEC2 in the promotion of HCC invasion and metastasis by epithelial-mesenchymal transition (EMT) detection.
Materials And Methods

Data Acquisition
Liver cancer mRNA expression data were downloaded from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). Gene microarray data (GSE39791, GSE14520, GSE36376, GSE89377, and GSE76427) were downloaded from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/ geo/). We used log2 transformation to transform the expression level of MAGEC2 mRNA for further analysis.
Tumour Tissue Specimens
A tissue microarray (TMA) containing ninety-five HCC samples and eighty-five noncancerous samples was purchased from Outdo Biotech Co., Ltd. (Shanghai, China) to conduct IHC analysis. The original clinical data were also provided along with the TMA. Moreover, a total of 39 formaldehyde-fixed and paraffin-embedded HCC samples were collected from the Department of Pathology, Jiangsu Cancer Hospital and divided into three groups for EMT detection: the primary HCC group (13 patients), the invasive group (13 patients) and the metastatic (vascular tumour thrombus) group (13 patients). All patients provided informed consent, and the study was approved by the ethics committee of each hospital.
Cells And Reagents
One HCC cell line (MHCC97H) was generously provided by Yuanduan Biological Co., Ltd. (Jiangsu, China). Two other HCC cell lines (SK-H-1 and HepG2) and the human liver cell line LO-2 were obtained from the cell bank of the Chinese Academy of Science (Shanghai, China). For MAGEC2 knockdown, the target sequence of the short hairpin RNA (shRNA) was as follows: 5ʹ-CCT CTT CCA CTT TGT ACT T -3ʹ (Gene ID: NM_016249). The shRNA targeting MAGEC2 (sh-MAGEC2) was cloned into pLKD-CMV-G&PR-U6-shRNA (Obio Technology, Co., Ltd., Shanghai, China). An unrelated random sequence was used as an sh-MAGEC2 negative control (sh-MAGEC2-NC). After viral transduction, MAGEC2 expression was evaluated by quantitative real-time polymerase chain reaction (qPCR) and Western blotting (WB) analyses. The primary antibodies, including MAGEC2, E-cadherin, N-cadherin, fibronectin, Slug, cleaved caspase-3, Cyclin D1, Cyclin E and Ki67, were all purchased from Abcam Co., Ltd. (Abcam, Cambridge, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA).
qPCR And WB Analyses
For qPCR, total RNA was extracted using TRIzol reagent (Vazyme Biotech Co., Ltd., Jiangsu, China) according to the manufacturer's guidelines. The primers for MAGEC2 were as follows: forward primer 5ʹ-GAA CAG TGT TGT TCA GCT TGG -3ʹ; reverse primer 5ʹ-GGA CAT TAC CTG GAG TAT CGG -3ʹ. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a normalization control. For WB analysis, the detailed protocols were described in our previous research. 10 
Immunohistochemistry (IHC) Analysis
For IHC analysis, TMA sections were incubated with a primary monoclonal rabbit anti-MAGEC2 antibody (1:100, Abcam, Cambridge, MA, USA). The detailed protocol for IHC analysis and the evaluation of MAGEC2 expression were defined in our previous report. 10 In short, the immunostaining intensity of MAGEC2 was categorized as follows: 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The immunostaining percentage of MAGEC2 was ranked as follows: 1 (0-10%), 2 (11-50%), 3 (51-80%), and 4 (81-100% The detailed protocols of cell apoptosis and cell cycle analyses were described previously. 12 Moreover, the expression of cleaved caspase-3, Cyclin D1 and Cyclin E was detected by WB analyses as described above.
Tumour Growth Assay In Vivo
Six-week-old male BALB/c nude mice were purchased from CAVENS Co., Ltd. (Changzhou, China). Equal numbers of cells (5×10 6 ) transfected with sh-MAGEC2 or sh-MAGEC2-NC and untransfected MHCC97H cells were injected subcutaneously into each mouse (n = 6 mice per group). Tumour size was recorded, and tumour volume was calculated as described previously. 13 At the end of the inoculation period (day 33), all mice were sacrificed, and xenograft tumours were collected for further analyses. The protocols of in vivo experiments were approved by the Institutional Animal Care and Use Committee of Southeast University (NO. 20180706007) and in accordance with the ethical standards of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health for Animal Welfare Act. In addition, Ki67 expression in xenografts from nude mice was also examined by IHC analysis as described above.
Detection Of EMT Markers By IHC And WB Analyses
The expression of EMT markers, including E-cadherin, N-cadherin, fibronectin and Slug, was detected by IHC and WB analyses as described previously.
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Statistical Analysis
The data are expressed as the mean ± standard deviation. Differences between 2 groups were statistically analysed using Student's t-test or the Mann-Whitney U-test. Multiple groups were compared using one-way analysis of variance (ANOVA) with least significant difference (LSD)'s post hoc correction or the Kruskal-Wallis nonparametric test followed by the Mann-Whitney U-test. P < 0.05 was considered significant. All statistical analyses were conducted using SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) and STATA 12.0 (Stata Corporation, College Station, TX, USA).
Results
Confirmation Of MAGEC2 Expression By Bioinformatics Analyses
After performing bioinformatics analyses, we found that MAGEC2 mRNA expression was significantly higher in liver cancer tissues than in normal liver tissues from the TCGA cohort (P = 0.000, Figure 1A ). Moreover, MAGEC2 mRNA was also overexpressed in HCC tissues compared to noncancerous tissues in the GSE39791 (P = 0.002, Figure 1B ), GSE14520 (P = 0.000, Figure 1C ), GSE36376 (P = 0.000, Figure 1D ) and GSE89377 (P = 0.000, Figure 1E ) gene microarrays from the GEO cohort.
Detection Of MAGEC2 Expression By IHC Analysis In The HCC TMA
By IHC analysis, high MAGEC2 expression was detected in 45 of 95 (47.4%) HCC tissues, while no MAGEC2 expression was detected in noncancerous tissues, and the difference was statistically significant (P = 0.000). MAGEC2 staining was localized in the nuclei of HCC cells, and representative IHC staining is illustrated in Figure 2A . High MAGEC2 expression was significantly correlated with tumour size (P = 0.017) and prognosis (P = 0.009) ( Table 1) .
Survival Analysis
In the GSE76427 microarray from the GEO cohort, a Kaplan-Meier curve was constructed to demonstrate that the high expression of MAGEC2 mRNA was associated with unfavourable relapse-free survival (RFS) (P = 0.036, Figure 2B ). In the HCC TMA, the univariate analysis revealed that MAGEC2 expression (P = 0.006) strongly correlated with overall survival (OS) in HCC, and the multivariate analysis further indicated that MAGEC2 expression (P = 0.008) was an independent prognostic factor for HCC patients (Table 2) . A Kaplan-Meier curve was also generated to illustrate that the overall survival was unfavourable in patients with high MAGEC2 expression compared with patients with low MAGEC2 expression (P = 0.0048, Figure 2C ).
Construction Of The MAGEC2-Knockdown Model
As shown in Figure 3A , qPCR revealed that MAGEC2 expression was significantly detected in the MHCC97H cell line but not in the LO2, HepG2 or SK-H-1 cell line. Then, a MAGEC2-knockdown model in the MHCC97H cell line was prepared by shRNA with lentiviral transfection, and the results of qPCR and WB analyses confirmed that MAGEC2 was significantly decreased in the sh-MAGEC2 group (P = 0.000, Figure 3B ). Fluorescence microscopy further showed that both the sh-MAGEC2 and control groups exhibited strong fluorescence, which validated the successful construction of sh-MAGEC2 in MHCC97H cells after lentiviral transfection for 72 h ( Figure 3C ).
MAGEC2 Affects The Malignant Behaviours Of HCC In Vitro
A series of the malignant behaviours of MAGEC2 was investigated. CCK-8 (P = 0.000, Figure 3D ), wound healing (P = 0.002, Figure 3E ) and transwell (P = 0.000, Figure 3F ) assays demonstrated that sh-MAGEC2 markedly inhibited cell growth, migration and invasions in HCC. Moreover, the Annexin V-APC/7-AAD assay illustrated that sh-MAGEC2 dramatically enhanced the apoptotic rate (P = 0.000, Figure 3G ). FCM demonstrated that the G1 phase was significantly prolonged in sh-MAGEC2 cells (P = 0.002, Figure 3H ), S phase was significantly shortened in sh-MAGEC2 cells (P = 0.001, Figure 3H ) while G2 phase was rarely changed (P = 0.054, Figure  3H ), suggesting that MAGEC2 critically promotes the G1/S phase transition. Furthermore, WB analysis showed that the expression of cleaved caspase-3 was higher in the sh-MAGEC2 group than in the sh-MAGEC2-NC group, which implies that MAGEC2 can inhibit cleaved caspase-3 expression, thereby explaining the suspension of apoptosis in HCC cells by MAGEC2 ( Figure 3I ). In addition, Cyclin E was downregulated while Cyclin D1 expression was unchanged in the sh-MAGEC2 group, which indicates that Cyclin E might participate in the cell cycle modulation by MAGEC2 in the G1-S transition in HCC cells ( Figure 3I ). To investigate the function of MAGEC2 in HCC development, we used three cell lines (MHCC97H untransfected, sh-MAGEC2 and sh-MAGEC2-NC) to construct HCC xenografts in nude mice. As shown in Figure 4A , the size of xenograft tumours in the sh-MAGEC2 group was remarkably smaller than those from the sh-MAGEC2-NC group or the MHCC97H untransfected group on day 33. Tumour volume curves and tumour weight comparisons also demonstrated that tumour growth was significantly decreased in the sh-MAGEC2 group compared with the sh-MAGEC2-NC group or the MHCC97H untransfected group (P = 0.002 and P = 0.003, Figure 4B and C, , b) ) FCM results showed that sh-MAGEC2 critically increased cell apoptosis. (H(a, b) ) FCM results showed that sh-MAGEC2 significantly prolonged the G1 phase and shortened the S phase. (I) Western blotting analyses showed that sh-MAGEC2 significantly elevated cleaved-caspase-3 expression and down-regulated Cyclin E expression. In comparison, there was no significant change for CyclinD1 by in sh-MAGEC2 group. **P < 0.01.
respectively). The expression of Ki67 in xenografts from nude mice was then detected by IHC analysis and demonstrated a significant reduction in the sh-MAGEC2 group, which further implied the stimulating role of MAGEC2 in tumour growth ( Figure 4D and E). All the above data strongly suggest that MAGEC2 dramatically enhances HCC development.
MAGEC2 Promotes HCC Invasion And Metastasis Via EMT
In the sh-MAGEC2 group, the results of IHC and WB analyses demonstrated that the expression of the epithelial marker E-cadherin (P = 0.009) was significantly elevated, whereas the expression levels of MAGEC2 (P = 0.007) and the mesenchymal markers N-cadherin (P = 0.000), fibronectin (P = 0.004), and Slug (P = 0.003) were remarkably decreased compared to the sh-MAGEC2-NC group or the MHCC97H untransfected group ( Figure 5A , C and E). Moreover, invasive and metastatic (vascular tumour thrombus) HCC samples exhibited reduced E-cadherin expression (P = 0.026) but increased MAGEC2 (P = 0.001), N-cadherin (P = 0.003), fibronectin (P = 0.012), and Slug (P = 0.027) expression compared to primary HCC samples ( Figure 5B and D). The above data imply that MAGEC2 promotes HCC invasion and metastasis via EMT.
Discussion
Although there are racial and regional differences in MAGEC2 expression, it is well acknowledged that targeting MAGEC2 has enormous potential in immunotherapy, and several MAGEC2-based immunotherapeutic strategies have been reported. For instance, Sideras et al 14 developed
a panel containing four tumour antigens (MAGEC1, MAGEC2, GPC-3 and Annexin) that may be suitable for vaccination studies in HCC patients in western, low-endemic areas. However, in eastern Asia, targeting MAGEC2 may provide a promising strategy for HCC treatment because of the predominant expression of MAGEC2. [14] [15] [16] [17] [18] However, the detailed characteristics of MAGEC2 in HCC tumourigenesis, as well as the underlying mechanisms, deserve further exploration. In the present study, after bioinformatics acquisition and IHC analysis, we found elevated MAGEC2 expression in HCC at both the mRNA and protein levels. Additionally, MAGEC2 expression was closely correlated with certain malignant behaviours in HCC patients, including tumour size, OS and RFS. The survival analysis further demonstrated that MAGEC2 expression is an independent prognostic factor for HCC patients. Collective studies support the notion that elevated MAGEC2 expression can be observed in different cancers 19, 20 There are several limitations to this study. First, the quality of the TMA is mediocre because the numbers of positive samples of lymph node metastases and distant metastases are small, and some important clinical information for HCC is missing (i.e., HBV/HCV infection, alcohol consumption, and vascular invasion). We believe that this is the main reason that we did not identify substantial relationships between MAGEC2 expression and lymph node and distant metastases. Second, we did not construct a lung metastasis model of HCC. However, a number of preliminary experiments concerning lung metastases are ongoing, including selection of the mouse type, confirmation of the cell loading position, and the identification of cell number and status. Third, we failed to examine the second HCC cell line with relatively low MAGEC2 expression for the purpose of constructing a MAGEC2 overexpression model, which could have strengthened the power of the present results. The main reason for this was that we did not identify an HCC cell line with low MAGEC2 expression. Fourth, the exact mechanism of MAGEC2 in HCC development remains obscure. In the present study, we found that MAGEC2 facilitated HCC development by increasing Cyclin E expression and inhibiting cleaved caspase-3 expression. We simultaneously observed that MAGEC2 could promote HCC tumourigenesis by inducing EMT. Hence, we suspect that there are deep relationships between apoptosis and EMT caused by MAGEC2 in HCC development. Two arrays, including the Cancer Phospho Explorer Antibody Array and the AKT Signalling Pathway Antibody Array, have been purchased from Wayen Bio Co., Ltd. (Shanghai, China), and related signalling pathway experiments are ongoing.
In summary, we demonstrated for the first time that elevated MAGEC2 expression was remarkably correlated with an unfavourable prognosis in HCC, and MAGEC2 might be identified as a novel independent prognostic factor for HCC. Moreover, MAGEC2 could enhance HCC development both in vitro and in vivo by inducing EMT. Our findings highlight the potential of MAGEC2 as a promising therapeutic target for HCC treatment.
Conclusion
In conclusion, this study is the first to report that high MAGEC2 expression is correlated with unfavourable survival in HCC patients and that MAGEC2 might be used as a prognostic factor for HCC. Moreover, MAGEC2 could promote HCC development by inducing EMT. These findings indicate that targeting MAGEC2 provides a potential strategy for HCC treatment. OncoTargets and Therapy
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